Effectiveness of Temozolomide for Recurrent Malignant Glioma
Author Information
Author(s): Dinnes J, Cave C, Huang S, Milne R
Primary Institution: Southampton Health Technology Assessment Centre, University of Southampton
Hypothesis
Does temozolomide improve survival and quality of life in patients with recurrent malignant glioma compared to standard treatments?
Conclusion
Temozolomide may increase progression-free survival but does not significantly impact overall survival.
Supporting Evidence
- Temozolomide may improve progression-free survival by 13% at 6 months.
- Median progression-free survival was reported to be 4 weeks longer in the temozolomide group.
- Patients receiving temozolomide showed improvements in health-related quality of life.
- The overall survival advantage was not statistically significant.
Takeaway
Temozolomide is a medicine that might help some people with brain tumors live a little longer without their cancer getting worse, but it doesn't help everyone live longer overall.
Methodology
A systematic review was conducted, including one randomized controlled trial and four uncontrolled studies, assessing the effectiveness of temozolomide in patients with recurrent malignant glioma.
Potential Biases
Potential biases due to lack of blinding and the nature of uncontrolled studies.
Limitations
The evidence base is weak, with only one RCT and several uncontrolled studies, limiting the ability to draw strong conclusions.
Participant Demographics
Patients included those with recurrent glioblastoma multiforme and anaplastic astrocytoma, some of whom had received prior chemotherapy.
Statistical Information
P-Value
0.019
Confidence Interval
95% CI: 5, 23
Statistical Significance
p=0.019
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website